

ThromboGenics Appoints Thomas Clay as New Board Member

Former government minister Patricia Ceysens to be proposed to the Board in 2012

Leuven, Belgium – 24 November 2011 – ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that Thomas Clay has been appointed as a non-executive director with immediate effect.

Thomas Clay (26) is Vice-President of East Hill Management Company, a US-based venture capital firm specializing in the lifescience sector. He is also a director of Golden Queen Mining Company Ltd., a development-stage gold mining company, and the Clay Mathematics Institute. Thomas has an AB degree from Harvard University in Classics and a Masters degree from Oxford University in Greek and Latin Languages and Literatures. Thomas replaces his father Landon Clay, who has resigned from the Board.

In addition, the Board will propose the nomination of Patricia Ceysens (46), a Flemish politician, as non-executive director at ThromboGenics' 2012 Annual Shareholder Meeting. Mrs. Ceysens was the Flemish minister of Economy, Foreign Policy and Foreign Trade from 2003 to 2004, and Flemish minister of Economics, Business, science, Innovation and Foreign Trade from 2007 to 2009. She studied law at the Catholic University of Leuven.

Prof Désiré Collen, Chairman and Founder of ThromboGenics, said: "I would like to welcome Thomas to the board. I believe that his skills and experience will help the Company achieve its growth targets as we enter a pivotal phase of our development. I am also pleased that Patricia has agreed to be nominated to the Board at our next Annual Shareholder Meeting. She has a clear understanding of how to capitalize on research and innovation and I am sure the company will be able to benefit from this expertise once she is appointed. Finally I would like to personally thank Landon for his support and commitment to ThromboGenics over many years. The funding from East Hill combined with Landon's strategic counsel have played a key role in our transition from an ambitious private business to a successful public company with significant potential."

- Ends -

For further information please contact:

ThromboGenics

Dr. Patrik De Haes, CEO

Tel: + 32 16 75 13 10
patrik.dehaes@thrombogenics.com

Chris Buyse, CFO

Tel: + 32 16 75 13 10
chris.buyse@thrombogenics.com

Citigate Dewe Rogerson

David Dible/ Nina Enegren/ Sita Shah

Tel: +44 (0) 207 638 95 71
nina.enegren@citigatedr.co.uk



About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative ophthalmic medicines. The Company's lead product ocriplasmin has completed two successful Phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (VMA). Ocriplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (anti-Factor VIII), a long-acting anticoagulant in Phase II, and TB-403 (anti-PIGF) in Phase Ib/II for cancer in partnership with Roche.

ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on NYSE Euronext Brussels under the symbol THR. More information is available at www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.